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- Adverse effects
-  Prescribing within clinical trials and availability of unlicensed medi-
cines
- License extension
Conclusion: This investigation found variation between actual 
uptake of new medicines and the predictions provided in Forward 
Look reports and SMC advice. The 7 factors identified assist in 
explaining the variations observed, are useful in understanding the 
challenges in making accurate predictions, and provide some areas 
in which action could be taken to further develop and potentially 
improve predictions in Forward Look reports and SMC advice.
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Introduction: Drug manufacturers developed “evergreening strate-
gies” to compete with generic medication after patent termination. 
These include marketing of slightly modified follow-on drugs. We 
identified 8 follow-on drugs available in the canton of Geneva during 
the study period: 3 drugs for which an isomer had been marketed 
(levocetirizine as follow-on drug of cetirizine; escitalopram/citalo-
pram; esomeprazole/omeprazole); 1 active metabolite (desloratidine 
– loratidine); 2 combination formulations of the originally patented 
drug (alendronic acid alone – alendronic acid combined with colecal-
ciferol; simvastatin alone – simvastatin with ezetimib); 1 slow-release 
formulation (zolpidem extended release); and 1 structural analogue 
(pregabaline – gabapentine). We aimed to estimate the financial 
impact of these drugs on overall health care costs.
Patients (or Materials) and Methods: The impact of evergreening 
strategies on health care spending was analyzed in the community 
database that includes > 73% of the total of insured patients. Costs 
were analyzed under 3 scenarios, assuming a replacement with the 
corresponding generic when available of: (1) all brand drug prescrip-
tions; (2) all follow-on; and (3) both follow-on and brand prescrip-
tions. The “extra-cost” was assessed by the difference between the 
total cost based on the observed data and the total cost estimated in 
the 3 scenarios.
Results: Based on our scenario 1 (no brand) and 2 (no follow-on) of 
“extra-costs,” the health care system could have saved over the entire 
study period € 15.9 (95% CI, 15.5–16.2) million and € 14.4 (95% CI, 
14.1–14.7) million if brand or follow-on drug prescriptions, respec-
tively, had replaced. This amounted to € 30.3 (95% CI, 29.8–30.8) 
million over the entire study period if brand and follow-on drug pre-
scriptions were replaced at their corresponding community generic 
selling price equivalents when available (scenario 3).
Conclusion: Evergreening strategies have been successful in maintain-
ing market share in Geneva, offsetting competition by generics and 
cost-containment policies. Therefore, health care providers and policy 
makers should be aware of the impact of evergreening strategies.
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Introduction: Intravenously administered Busulfan (Bu) in children 
undergoing hematopoietic stem cell transplantation (HSCT) exhibits 
therapeutic window phenomenon requiring therapeutic drug moni-
toring. The dosage of Bu is adjusted based on the first dose phar-
macokinetic parameters. Existing methods for the analysis of Bu 
require long turnaround times with relatively large amounts of blood 
collection for plasma separation.
Objective: To evaluate the utility of dried blood sampling (DBS) 
and dried plasma sampling (DPS) using only 5 μ L of whole blood or 
plasma for therapeutic monitoring of Bu levels.
Patients (or Materials) and Methods: Venous blood samples were 
collected from 2 children after the infusion of Bu at doses1, 2, 3, 5, 
and 9 (n = 34). Then, 5 μ L each of whole blood and plasma were 
spotted onto Whatman 903 DBS cards and dried at room tempera-
ture for 30 minutes. The entire spots were cut and then analyzed by 
a validated LC-MS/MS method. Bu was also measured by established 
gas chromatography coupled to mass spectrometry (GC-MS) method 
using plasma (n = 13) to compare both the methods.
Results: A good correlation was observed between the levels meas-
ured by DBS and DPS (r2 = 0.95; slope = 0.84). The Bu levels meas-
ured by DPS (r2 = 0.92; slope = 0.95) and DBS (r2 = 0.91; slope = 
0. 80) were correlated with those measured by GC-MS method. The 
levels estimated by DBS were less than those obtained by DPS and 
GC-MS methods. The hematocrit (Hct) values of 2 children were in 
the range of 25.6% to 30.3%, indicating the direct influence of Hct 
on the measured Bu levels measured by DBS sampling. Therefore, 
these 2 sampling methods can be used interchangeably with due con-
sideration of the Hct value when whole blood sample is used. The 
plasma levels can be obtained from DBS levels using the formula 
“Plasma levels (analyte) = DBS levels analyte/ (1 – hematocrit).” The 
plasma levels of Bu estimated using this formula were higher than 
